⚡ Flash Summary

Citi Pharma Limited (CPHL) has announced a final cash dividend of Rs.3.5 per share, which represents 35% for the year ended June 30, 2025. The dividend has been credited electronically to the designated bank accounts of shareholders on November 05, 2025. The dividend payment for shareholders who have not provided their valid IBAN and CNIC has been withheld, in accordance with regulatory requirements. This distribution adheres to the Companies (Distribution of Dividends) Regulations, 2017, and the Companies Act, 2017.

📌 Key Takeaways

• 💰 CPHL declares a final cash dividend of Rs.3.5 per share.
• 📅 The dividend represents 35% for the year ended June 30, 2025.
• 🏦 Dividends were electronically credited to shareholders’ bank accounts on November 05, 2025.
• 🏦 IBAN and CNIC details are necessary for dividend disbursement.
• 🚫 Dividend payments are withheld for shareholders lacking valid IBAN and CNIC.
• 📜 The dividend distribution complies with the Companies Act, 2017, and related regulations.
• 🇵🇰 The company is listed on the Pakistan Stock Exchange.
• 🏢 Ghulam Dastgeer, the Company Secretary, signed the announcement.
• 📍 The company headquarters is located in Lahore, Pakistan.
• 🏭 The factory is located in Kasur, Pakistan.
• 🌐 More information is available on the company’s website: www.citipharma.com.pk

🎯 Investment Thesis

Based on the dividend announcement, a HOLD recommendation is appropriate. The dividend provides a return to shareholders, but further analysis is needed to assess the company’s overall financial health and future prospects. A price target cannot be accurately determined without more comprehensive financial information. The time horizon for this recommendation is medium-term, pending further financial analysis and monitoring of company performance.